$82.04
0.53%
Nasdaq, Nov 17, 03:59 pm EST. Closed.
ISIN
US2521311074
Symbol
DXCM

DexCom, Inc. Target price 2026 - Analyst rating & recommendation

DexCom, Inc. Classifications & Recommendation

Buy
89%
Hold
11%

DexCom, Inc. Price Target

Target Price $97.92
Price $82.04
Potential 19.36%
Number of Estimates 30
30 Analysts have issued a price target DexCom, Inc. 2027 . The average DexCom, Inc. target price is $97.92. This is 19.36% higher than the current stock price. The highest price target is $126.00 53.58% , the lowest is $75.75 7.67% .
A rating was issued by 36 analysts: 32 Analysts recommend DexCom, Inc. to buy, 4 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the DexCom, Inc. stock has an average upside potential 2027 of 19.36% . Most analysts recommend the DexCom, Inc. stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2030

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion $ ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

32 Analysts have issued a sales forecast DexCom, Inc. 2026 . The average DexCom, Inc. sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 $4.7b 15.60%
2026
2027
2028
2029
2030

28 Analysts have issued an DexCom, Inc. EBITDA forecast 2026. The average DexCom, Inc. EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $1.3b 44.21%
2026
2027
2028
2029
2030

EBITDA Margin

2025 26.95% 24.76%
2026
2027
2028
2029
2030

33 DexCom, Inc. Analysts have issued a net profit forecast 2026. The average DexCom, Inc. net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $836m 45.14%
2026
2027
2028
2029
2030

Net Margin

2025 17.94% 25.56%
2026
2027
2028
2029
2030

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2030

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ ??? ???
??? ???
P/E ???
EV/Sales ???

33 Analysts have issued a DexCom, Inc. forecast for earnings per share. The average DexCom, Inc. EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $2.06 47.14%
2026
2027
2028
2029
2030

P/E ratio

Current 31.63 3.57%
2026
2027
2028
2029
2030

Based on analysts' sales estimates for 2026, the DexCom, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 5.86 21.33%
2026
2027
2028
2029
2030

P/S ratio

Current 5.96 18.91%
2026
2027
2028
2029
2030

Current DexCom, Inc. Upgrades & Downgrades

Analyst Rating Action Date
Barclays
Overweight
➜
Overweight
Unchanged Oct 30 2026
UBS
Buy
➜
Buy
Unchanged Oct 30 2026
StoneX
Buy
➜
Buy
Unchanged Oct 30 2026
Canaccord Genuity
Buy
➜
Buy
Unchanged Oct 30 2026
JP Morgan
Neutral
➜
Neutral
Unchanged Oct 30 2026
BTIG
Buy
➜
Buy
Unchanged Oct 12 2026
Barclays
➜
Overweight
Initiated Oct 07 2026
Analyst Rating Date
Unchanged
Barclays:
Overweight
➜
Overweight
Oct 30 2026
Unchanged
UBS:
Buy
➜
Buy
Oct 30 2026
Unchanged
StoneX:
Buy
➜
Buy
Oct 30 2026
Unchanged
Canaccord Genuity:
Buy
➜
Buy
Oct 30 2026
Unchanged
JP Morgan:
Neutral
➜
Neutral
Oct 30 2026
Unchanged
BTIG:
Buy
➜
Buy
Oct 12 2026
Initiated
Barclays:
➜
Overweight
Oct 07 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today